Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
4.720
+0.285 (6.43%)
At close: Aug 13, 2025, 4:00 PM
4.680
-0.040 (-0.85%)
Pre-market: Aug 14, 2025, 8:57 AM EDT
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,499,715
Market Cap
7.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 1 | 33.33% |
| Dec 31, 2021 | 3 | 0 | - |
| Dec 31, 2020 | 3 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ACXP News
- 1 day ago - Acurx Pharmaceuticals, Inc. (ACXP) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Acurx Pharmaceuticals, Inc. Reports Second Quarter Results and Provides Business Update - PRNewsWire
- 13 days ago - Acurx Pharmaceuticals, Inc. Announces Reverse Stock Split - PRNewsWire
- 21 days ago - Acurx Pharmaceuticals to Discuss Second Quarter 2025 Financial Results on August 12, 2025 Conference Call and Provide Business Update - PRNewsWire
- 2 months ago - Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds - PRNewsWire
- 2 months ago - Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI - PRNewsWire
- 2 months ago - Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Federation of American Societies for Experimental Biology Scientific Conference - PRNewsWire
- 3 months ago - Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call Transcript - Seeking Alpha